We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Evaluation of Rapid Rabies Tests Reveals Problems with Accuracy

By LabMedica International staff writers
Posted on 06 Jul 2016
Print article
Image: The Rapid Rabies Ag Test Kit is a chromatographic immunoassay for the qualitative detection of Rabies virus antigen (Photo courtesy of Creative Diagnostics).
Image: The Rapid Rabies Ag Test Kit is a chromatographic immunoassay for the qualitative detection of Rabies virus antigen (Photo courtesy of Creative Diagnostics).
If humans bitten by a rabid animal are treated quickly, the disease can usually be prevented but such post-exposure prophylaxis is expensive and should be reserved for bites from animals with confirmed infection, but testing dogs for rabies in resource-poor settings is challenging.

The gold standard for rabies diagnosis is the fluorescence antibody test (FAT), which requires that brain tissue is fixed on microscope slides, stained with fluorescently labelled antibodies, and examined under a fluorescence microscope. Alternative diagnostics include various assays to detect virus, antigen or viral ribonucleic acid (RNA), the latter based on polymerase chain reaction (PCR) technology. All of these tests require laboratory equipment, trained staff, and temperature-sensitive reagents.

Scientists at the Friedrich-Loeffler-Institute (Greifswald-Insel Riems, Germany) and their international colleagues compared six commercial lateral flow devices (LFD) for the diagnosis of rabies and their analytical sensitivity. They examined the sensitivity of the tests, their ability to exclude rabies infection accurately, as well as their specificity, which reflects an accurate positive diagnosis, in comparison with fluorescent antibody tests (FAT) and PCR in over 100 samples from experimentally infected animals and animals infected in the wild.

The investigators found that while all six tests showed good specificity, that is none gave false positives, they found that none of them demonstrated good sensitivity across the different sample sets. In fact, more than half of all positive samples, those with positive FAT and PCR results yielded "false negative" LFD results. Some LFD tests did better than others, and in some cases specific batches of the same test did better than others, but overall the results were disappointing.

The Antigen Rapid Rabies Ag-Test (Bionote Inc, Hwaseong-si, South Korea) displayed a positive rate for seven samples; the Rabies Virus Ag Rapid Test (Green Springs, Shenzhen, China) for 10 samples; the Rapid Rabies Ag Test (Creative Diagnostics, Shirley, NY, USA) for 14 samples. The scientists did report that viral RNA can be stored and eventually extracted from the LFDs using standard procedures available at molecular diagnostic laboratories. In fact, they were able to detect viral RNA after six weeks of storage at room temperature.

The authors concluded that with their current limitations commercially available rabies LFDs cannot be recommended for routine diagnosis and surveillance. If animals were involved in a biting incident to a human being, they note that false negative results may induce the patient and the doctor to refrain from appropriate post-exposure prophylaxis (PEP) given its high cost, even if the leaflet accompanying the test states that results are to be confirmed by a reference method. The study was published on June 23, 2016, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Friedrich-Loeffler-Institute
Bionote
Green Springs
Creative Diagnostics
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.